SPRONasdaqPharmaceutical PreparationsFiscal year ends December 31
Spero Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.12+0.02 (+1.82%)
Close on Oct 19, 2026
- Market cap
- $64.92M
- P/E (TTM)
- 28.0
- Dividend yield
- –
Spero Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | % of revenue | YoY |
|---|---|---|---|---|---|
| Collaboration revenue - related party | $47.03M | $27.03M | $95.80M | 70.4% | +74.0% |
| Collaboration revenue | $12.59M | $371.00K | $933.00K | 18.8% | +3292.5% |
| Grant Revenue | $7.18M | $20.58M | $7.05M | 10.8% | -65.1% |
By region
From the segment and revenue-disaggregation notes of Spero Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.